Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31559989 | 0.87 | APP (0.34) | — | |
| SCHEMBL27604192 | 0.87 | MAPT (0.33) | — | |
| SCHEMBL28789047 | 0.81 | XDH (0.41) | — | |
| SCHEMBL316146 | 0.79 | THRB (0.32) | THRBTDP1AKR1C1 | |
| SCHEMBL2121108 | 0.78 | SRR (0.32) | THRBTDP1AKR1C1 | |
| Hydrochloric Acid SCHEMBL2219432 | 0.78 | THRB (0.32) | THRBTDP1AKR1C1 | |
| SCHEMBL21328421 | 0.78 | THRB (0.32) | THRBTDP1AKR1C1 | |
| SCHEMBL28256376 | 0.78 | THRB (0.32) | THRBTDP1AKR1C1 | |
| SCHEMBL1119645 | 0.78 | THRB (0.35) | THRBTDP1AKR1C1 | |
| Hydrochloric Acid SCHEMBL8006256 | 0.78 | THRB (0.32) | THRBTDP1AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304065-B2 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | claimed |
| CN-101068773-A | Melanin concentrating hormone antagonists | PROCTER & GAMBLE (US) | 2007-11-07 | — | — | CN | claimed |
| CN-113631548-B | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-113045494-B | Pyridone derivative and application thereof in preparation of drugs for preventing and/or treating tuberculosis caused by mycobacterium tuberculosis | 四川大学华西医院 | 2022-04-26 | — | — | CN | disclosed |
| CN-113631548-A | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113045494-A | Pyridone derivative and application thereof in preparation of drugs for preventing and/or treating tuberculosis caused by mycobacterium tuberculosis | 四川大学华西医院 | 2021-06-29 | — | — | CN | disclosed |
| CN-102282139-B | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN LA ROCHE | 2014-06-18 | — | — | CN | disclosed |
| CN-102282139-A | Piperidine derivatives as nk3 receptor antagonists | — | 2011-12-14 | — | — | CN | disclosed |
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| CN-101068773-A | Melanin concentrating hormone antagonists | PROCTER & GAMBLE (US) | 2007-11-07 | — | — | CN | disclosed |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-06-07 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1667958-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005033063-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1432693-A2 | MCH RECEPTOR ANTAGONISTS | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028641-A2 | MCH RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | OXTR, GPR6, CNR1 | THRB 1309/4885TDP1 3428/4885AKR1C1 244/4885 |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | THRB 44/4885TDP1 3389/4885AKR1C1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.